Evercore ISI Group Maintains Outperform on NovoCure, Lowers Price Target to $20
Benzinga Newsdesk 3 weeks ago
Analyst RatingsNewsPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Evercore ISI Group analyst Vijay Kumar maintains NovoCure (NASDAQ:NVCR) with a Outperform and lowers the price target from $23 to $20.
Evercore ISI Group analyst Vijay Kumar maintains NovoCure (NASDAQ:NVCR) with a Outperform and lowers the price target from $23 to $20.
